HEALY JAMES

Director James Healy bought 666,665 shares at $18.00 ($12.0M); cluster pattern with 4 other insiders buying within 14 days

Director James Healy executed 5 separate purchases totaling 666,665 shares for $11,999,970.00 at $18.00 per share on 2024-09-27. The transaction occurred in a context of recent listing (just 2 trading days), where the current market price is $21.00. This substantial acquisition is noteworthy because 4 other insiders also bought within the past 14 days, forming a cluster buy pattern. The filing contains a derivative conversion (Form 4 Table II), meaning the 26,497 shares shown in Table I post-transaction represents only a portion of the director's total position; the derivative holdings are not yet populated in the database. This multi-insider buying activity in the days following a stock listing suggests coordinated confidence or planned accumulation tied to the IPO process.

Director James Healy purchases 44,032 shares at $23.30–$26.06 in 12 transactions totaling $1.1M at recently-listed RAPP

James Healy, a director at Rapport Therapeutics, executed 12 separate purchases on 2024-07-01, acquiring 44,032 shares totaling $1,079,575.36 at prices ranging from $23.08 to $26.06, with a blended average of $24.52. This substantial commitment—representing a net addition to his holdings from a negative position to 40,851 shares—occurred just 18 trading days after the company's recent listing. The multi-tranche structure and rapid execution suggest a deliberate accumulation rather than opportunistic activity. With the stock currently trading at $23.30 as of 2024-07-03, the director's purchase prices span slightly above and below the current level, positioning his position during RAPP's nascent public trading phase.